ELN indicates that molecular evaluation of PML-RARA, RUNX1/RUNX1T1, CBFB-MYH11 and mutated NPM1 need to be considered as a standard of care for AML patients, and it recommends performing that assessment at diagnosis and every 3 months for 24 months after treatment editing [16]. This evidence concerns the gene RARA and acute myeloid leukemia.